Compass Therapeutics (CMPX) Interest Expenses (2018 - 2021)

Compass Therapeutics has disclosed Interest Expenses across 4 years of filings, most recently posting $39000.0 for Q4 2021.

• Interest Expenses for Q4 2021 came in at $39000.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2022 was $39000.0 (down 82.27% YoY), and the FY2021 annual result was $370000.0, down 59.25% from the prior year.
• Interest Expenses came in at $39000.0 for Q4 2021 at Compass Therapeutics, down from $78000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $314000.0 in Q2 2019 to a low of $580.0 in Q2 2018.
• The 4-year median for Interest Expenses is $110000.0 (2021), against an average of $134889.2.
• Across the five-year window, Interest Expenses surged 54037.93% in 2019 and slumped 63.21% in 2021, its largest moves.
• Compass Therapeutics' Interest Expenses stood at $875.0 in 2018, then jumped by 65.03% to $1444.0 in 2019, then soared by 14581.44% to $212000.0 in 2020, then plunged by 81.6% to $39000.0 in 2021.
• The last three Interest Expenses figures came in at $39000.0 (Q4 2021), $78000.0 (Q3 2021), and $142000.0 (Q1 2021), per Business Quant data.